• Brera Holdings, an Ireland-based, international holding company with a global portfolio of men’s and women’s sports clubs, just closed 10 new signings for its clubs in the 2024-2025 transfer window, 8 for the men’s teams and 2 for the women’s teams
• The company’s management believes that these new signings will bring fresh energy and expertise to their respective teams, positioning them for a successful second half of the season
• The signings follow an independent CFA’s valuation report projecting Brera’s revenues will triple in 2025

Brera Holdings (NASDAQ: BREA), an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership (“MCO”) approach, announced its new signings for its portfolio clubs ahead of the spring championship. According to its management, these additions reflect the company’s ongoing commitment to player development and expanding talent pathways, mainly from Africa and Eastern Europe (https://ibn.fm/7TLll).

The clubs that will benefit from these transfers include those in North Macedonia: Brera Strumica (mens), and Brera Tiverija (womens). The signees include Fodey Tavali (midfielder), Dragan Bilbia (defender), Fahd Nzengue (forward), Hadji Drame (right wing), Filip Mihailov (midfielder/attacker), Zoran Ivanovski (wing), Hristijan Jankuloski (defender) and Mihail Milevski (midfielder/defender), to cover the men’s team. Christine Nafula (forward) and Danche Karpuzzovska (midfielder/forward) will be the new additions to the women’s team.

The women’s team currently ranks first in their league, earning the title “winter champions.” Their two new additions, its management notes, will look to strengthen its position and defend its title this spring. In addition, the new signings, overall, will bring fresh energy and expertise into the respective teams, positioning them for a successful second half of the season (https://ibn.fm/7TLll).

These signings follow analyst projections that Brera’s revenues will triple in 2025. It was projected by an independent CFA report that for the 2025 financial year, the company will realize revenues of between $6.3 million and $9.8 million. While primarily influenced by the SS Juve Stabia acquisition of “The Second Team of Naples” in Italy’s Serie B, signings for the male and female teams in its portfolio also boost shareholder confidence and help drive the company’s earnings going forward.

“Brera Holdings made a strategic move with the Juve Stabia acquisition, and while challenges remain, the company is positioning itself for significant revenue growth,” noted Sascha P. Czerwenka, CFA, for 247MarketNews.com. “If operational improvements continue as expected, the stock could see a major re-rating, presenting a compelling opportunity for investors,”he added (https://ibn.fm/kf4Jr).

Brera remains committed to building competitive squads with diverse international talent, with its expansion into markers such as Asia and Africa being a testament to that.

For company information, visit the company’s website at www.BreraHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA

• Forschungszentrum Jülich scientists have already leveraged D-Wave’s technology for research on protein folding, electron interactions and quantum physics.
• The Advantage™ system features over 5,000 qubits and 15-way connectivity, advancing quantum optimization research.
• The quantum system will be linked to JUPITER, Europe’s first exascale supercomputer, potentially enabling novel computational applications.
• The system will be upgraded to D-Wave’s next-generation Advantage2™ quantum processor when available, which D-Wave expects will deliver doubled coherence time, higher qubit connectivity and 40% improvement in energy scaling.
• The collaboration is anticipated to take the use of quantum technology to a new level, according to Prof. Kristel Michielsen, head of JUNIQ & Quantum Computing at the Jülich Supercomputing Centre.

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, and the first supplier of production-grade quantum computers, recently announced that the Jülich Supercomputing Centre (“JSC”) at Forschungszentrum Jülich (“FZJ”) has become the world’s first high-performance computing (“HPC”) center to purchase a D-Wave^TM Advantage annealing quantum computing system (https://ibn.fm/KGsAg).

The D-Wave system will be housed at the JSC, which provides computing resources for European researchers on supercomputers. JUNIQ, JSC’s European quantum computing infrastructure, gains complete access to all aspects of the D-Wave Advantage system.

“The D-Wave Advantage system has played a pioneering role in the development of quantum optimization, both through its contribution to breakthrough research and the development of enterprise-grade solutions across numerous industries,” said Prof. Thomas Lippert, director of JSC. “D-Wave stands alone as the only quantum vendor solving real-world problems today, and we’re thrilled to be the first HPC center in Europe to own its groundbreaking annealing quantum computer.”

The Advantage system acquired by JSC features:

• 5,000+ superconducting qubits
• 15-way qubit connectivity, allowing for more efficient quantum optimization
• Annealing-based quantum computing, designed for tackling real-world problems

FZJ plans to integrate the system with JUPITER, Europe’s first exascale supercomputer, which is under construction at JSC. FZJ expects JUPITER to exceed the threshold of one quintillion calculations per second. Once the integration is complete, FZJ and D-Wave expect it will be the world’s first coupling of an annealing quantum computer with an exascale supercomputer, providing a first-of-a-kind opportunity for tackling the world’s toughest computational problems. By linking D-Wave’s quantum technology with JUPITER, JSC may pave the way for advances in AI optimization, materials science and chemistry, financial modeling and logistics.

“With D-Wave’s innovative technology, the integration of the system into JUNIQ and its future coupling with the exascale supercomputer JUPITER, we will take the use of quantum technology in Jülich, and on behalf of Germany and Europe, to a new level,” said Prof. Kristel Michielsen, head of JUNIQ & Quantum Computing at JSC. “Our experts are familiar with hosting the system, and JUNIQ’s scientific users have already been able to conduct remarkable research. We look forward to the further use of D-Wave and its coupling with the new exascale supercomputer generation, which we hope will enable us to look at scientific questions in a completely new way and solve real-world problems.”

The acquisition builds on FZJ’s history of leveraging D-Wave’s quantum systems for cutting-edge scientific research. Some key past projects include:

• Protein Folding Studies: Researchers at Lund University in Sweden and JSC used D-Wave’s quantum computer to study protein folding, a critical area in understanding diseases like Alzheimer’s and Parkinson’s. The research was recognized in Physical Review Research.
• Electron Interaction Research: In 2024, JSC and colleagues from Slovenia demonstrated how an annealing quantum computer can directly simulate electron interactions, with results published in Nature Communications.
• Quantum Cosmology Simulations: A collaboration between JSC, University of Leeds and the Institute of Science and Technology Austria used D-Wave’s system to gain insights into the formation of the universe, with findings published in Nature Physics.

JSC’s D-Wave system is set to be upgraded to Advantage2, D-Wave’s next-generation quantum computer, once available, which is expected to deliver doubled coherence time, higher qubit connectivity and 40% improvement in energy scaling. This upgrade will further enhance JSC’s quantum computing capabilities, allowing for the pursuit of more complex problem-solving and scientific breakthroughs.

“JSC’s renowned HPC computing expertise combined with our transformational annealing quantum computing technology creates a powerful synergy,” said Dr. Alan Baratz, CEO of D-Wave. “We are excited to see the innovations and applications that we expect will continue to emerge from this important collaboration.”

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world’s first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our 5,000+ qubit Advantage quantum computers, the world’s largest, are available on-premises or via the cloud, supported by 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our Advantage systems and Advantage2^TM prototype systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we’re shaping the quantum-driven industrial and societal advancements of tomorrow: www.dwavequantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

• Clene is partnering with APST Research GmbH to analyze neurofilament light chain (“NfL”) data for evaluating CNM-Au8^® in ALS patients.
• APST maintains one of the largest ALS biomarker databases, with data from over 4,300 ALS patients, including clinical outcomes and biomarker tracking.
• The analysis will compare NfL changes in the NIH-sponsored Expanded Access Program (“EAP”) participants with historical ALS patient data to assess CNM-Au8’s potential efficacy.
• Clene plans to submit its statistical analysis plan to the FDA, aiming for filing of an NDA for potential accelerated approval in the second half of 2025.
• No significant safety concerns have been reported across over 800 participant years of CNM-Au8 treatment.

Clene Inc. (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), has signed an agreement with APST Research GmbH (“APST”) to support analyses of CNM-Au8’s effects on NfL decline in participants in ongoing EAPs (https://ibn.fm/2IwhG). The analyses were recommended by the U.S. Food and Drug Administration (“FDA”) to support Clene’s data package for a potential accelerated approval application.

Based in Germany, APST operates one of the largest ALS biomarker repositories, with data on over 4,300 ALS patients, including demographic information, motor function, and NfL biomarkers. This collaboration will provide Clene with robust comparative data to assess CNM-Au8’s potential efficacy in reducing NfL levels. Neurofilament light chain is a well-established biomarker for neuronal damage. In ALS, elevated NfL levels indicate disease progression and neuronal degeneration. Tracking how NfL levels change over time provides insight into whether a drug is slowing disease progression.

Under this agreement, Clene will use APST’s extensive dataset to compare NfL levels in NIH EAP participants treated with CNM-Au8 against historical ALS controls. The NfL dataset Clene is analyzing includes data from more than 1,625 ALS patients, aligning the biomarker data of NfL to clinical ALSFRS-R assessments, slow vital capacity (“SVC”), and clinical events such as ventilation support and nutrition intervention. The goal is to determine if CNM-Au8 treatment reduces NfL decline, and to demonstrate that the rate of NfL change is associated with survival in people living with ALS, which could strengthen Clene’s case for regulatory approval.

Commenting on the agreement, APST’s founder and CEO Thomas Meyer, a renowned ALS key opinion leader, emphasized the value of real-world biomarker data, noting that the collaboration advances ALS research and clinical development. “Our extensive and robust data collection empowers pharmaceutical companies to advance their clinical research and trials, driving us toward a deeper understanding of ALS disease progression” Meyer said.

Clene has provided CNM-Au8 treatment to nearly 500 ALS patients through its three EAP programs, collecting real-world evidence to assess the drug’s impact. Key aspects of Clene’s NfL analysis plan to be submitted to the FDA include:

• Comparing NfL changes in NIH-sponsored EAP participants to control data from APST.
• Analyzing correlations between NfL levels and patient survival rates.
• Supporting the case for FDA accelerated approval of CNM-Au8 in ALS treatment.

Clene plans to submit a new drug application (“NDA”) to the FDA in the second half of 2025 for potential accelerated approval. The NDA will contain data on NfL changes and survival with CNM-Au8 treatment, including results of this study.

CNM-Au8 is an oral suspension of gold nanocrystals designed to improve cellular energy production and utilization, which is critical for maintaining neuronal health. The drug candidate has been shown to improve central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the nicotinamide adenine dinucleotide pathway while reducing oxidative stress. By targeting mitochondrial dysfunction, CNM-Au8 can provide neuroprotection and promote remyelination. Across 800 participant years of CNM-Au8 treatment, no significant safety concerns or adverse events have been reported. Investigators have not identified any serious adverse events linked to the treatment.

“We are excited to enter into this endeavor with one of the world’s largest ALS NfL datasets in order to supplement available biomarker NfL data from our NIH-sponsored EAP, and to support the existing clinical study data for the potential review of an application for approval of CNM-Au8 in ALS via an accelerated regulatory pathway,” said Clene’s CEO, Rob Etherington. “We remain dedicated to the ALS community and are honored to continue our efforts to help critically ill patients and their families.”

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• Healthcare providers are increasingly prioritizing specific, high-impact AI applications that enhance patient care and financial performance.
• Adageis’ ProActive Care Platform leverages AI to enhance risk assessment, workflow optimization, and revenue tracking for providers.
• AI-driven patient monitoring and early intervention reduce hospital readmissions and improve care quality.
• Adageis’ Patented Risk Engine helps healthcare providers proactively address high-risk patients, improving outcomes while increasing reimbursements.
• Seamless integration with multiple EHR systems ensures easy adoption without disrupting provider workflows.

As in other areas, artificial intelligence is making a measurable impact on healthcare, but the focus is shifting. While artificial general intelligence (“AGI”) once dominated AI discussions, healthcare providers are now increasingly prioritizing specific, high-impact AI use cases and applications that enhance patient care and financial performance. This transition is being driven by value-based care models, which require providers to demonstrate improved patient outcomes rather than simply increasing service volume.

Companies like Adageis, a leading healthcare technology company, are at the forefront of this shift, delivering AI-driven tools that optimize patient care, track revenue, and improve operational efficiency. Adageis develops AI-centric solutions tailored to providers, Accountable Care Organizations (“ACOs”), and Clinically Integrated Networks (“CINs”). Its ProActive Care Platform is designed to integrate seamlessly into existing workflows, offering practical applications that directly impact revenue generation and patient care.

Key areas where Adageis’ AI solutions are making a difference:

• Risk Identification & Early Intervention: The Patented Risk Engine analyzes patient data to identify individuals at risk for chronic diseases or complications. By flagging high-risk patients early, providers can proactively intervene, reducing hospital readmissions and lowering costs.
• Revenue Tracking & Forecasting: Adageis simplifies value-based care revenue management by providing real-time insights into provider performance. AI-driven analytics ensure accurate revenue tracking across multiple providers, making it easier to align with payer incentives.
• Clinical Decision Support: The platform integrates with nearly 100 electronic health record (“EHR”) systems like AthenaHealth, Cerner, eClinicalWorks, Allscripts, and Epic, offering real-time insights at the point of care. This ensures that clinicians receive actionable recommendations without disrupting workflows.
• Administrative Task Automation: Beyond clinical applications, Adageis helps providers manage supply chains, resource allocation, and documentation, increasing efficiency and reducing administrative burdens.
• Continuous Patient Monitoring: AI-powered efficiency monitoring tools allow real-time tracking of patient health trends, ensuring timely interventions between visits. This leads to fewer emergency department visits and better overall patient outcomes.

The healthcare industry’s transition to value-based care is well underway, but many providers struggle with the financial complexities of this model. AI tools like those developed by Adageis help organizations meet value-based care metrics, ensuring they maximize reimbursements while improving patient care.

Adageis’ Value-Based Care Engine provides automated performance tracking to ensure compliance with payer requirements, optimized patient care strategies that improve reimbursement rates, as well as advanced analytics that help providers predict and manage costs. By streamlining complex processes, Adageis makes it easier for healthcare organizations to generate revenue while improving patient outcomes.

As AI continues to evolve, the shift from AGI to highly targeted applications in healthcare will accelerate. Companies like Adageis are demonstrating how AI can deliver tangible results, helping providers navigate the challenges of value-based care with precision and efficiency, improving financial performance, and enhancing patient outcomes—all without adding complexity to providers’ workflows.

“We offer a solution that meets everyone’s needs, helping providers and organizations drive revenue by delivering high-quality care, which everyone can align with,” Adageis CEO Shane Speirs said recently. “Much of the value in value-based care comes from providing proper documentation to patients and being proactive with screenings. We provide an easy solution for practices to indicate the metrics needed for patients, to provide high-quality care while maximizing incentive dollars.”

For more information, visit the company’s website at www.Adageis.com.

NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis

• Electronic monitoring (“EM”) technology developer SuperCom has developed a full range of best-in-class technology products and accompanying services to help criminal justice agencies reduce recidivism and incarceration costs while increasing rehabilitation potential for offenders
• The company recently reported a new contract win, its seventh domestic violence EM project on a national level
• In addition to national contract expansion throughout Europe, SuperCom has reported 20 new EM contracts throughout the United States
• Market analysts have noted the growing call for EM products and services, with marked increased usage in North America, Latin America, and Europe in recent years, underscoring SuperCom’s continued growth

SuperCom (NASDAQ: SPCB), a company specializing in electronic monitoring (“EM”) technology to help public safety agencies reduce the incidence of repeated domestic violence (“DV”), is announcing a new EM contract win that expands its portfolio of national DV monitoring projects.

The use of EM technology as an alternative to incarceration has been increasing on a global scale since public safety agencies in the United States began working with it in the 1980s. Last year, market analysts at ResearchAndMarkets.com and Berg Insight both reported that the number of participants in EM programs reached about 518,000 in North America, 130,000 in Latin America, and 64,000 in Europe during 2023 (https://ibn.fm/dZEL2).

The analysts forecast the number of participants in these EM programs will increase to about 680,000 in North America, 239,000 in Latin America, and 94,000 in Europe by 2028, underscoring the rising pace of new participants as government officials seek the means for cutting prison system costs while continuing to ensure the safety of their communities.

Overall, Berg reported that by the end of 2023, nearly 1.4 million people had participated in an EM supervision program, with nearly two-thirds of them in the United States (https://ibn.fm/BR3VF). SuperCom’s latest contract brings its current list of national EM of DV projects to seven, including announced services for the state police of Latvia (https://ibn.fm/eDQds) and Romania’s Ministry of Interior (https://ibn.fm/S7O7k).

The company noted it is outpacing its competitors with its expansion and is demonstrating its reputation as a leader in providing DV monitoring solutions. In addition to its large ongoing European expansion, SuperCom has signed 20 new contracts for technological solutions throughout the United States since last August, including services in six states where SuperCom’s products are being used for the first time (https://ibn.fm/VpDhJ).

The company also notes the technology’s potential for reducing recidivism (repeated offenses) by helping suspects and convicted offenders who qualify for EM monitoring to return to everyday work, school, and home activities while wearing a tech device that is discreet and easily recharged.

“We are pleased to see another national government choose our DV advanced electronic monitoring solutions, demonstrating the strong trust governments place in our technology and their satisfaction with its effectiveness,” SuperCom President and CEO Ordan Trabelsi stated in the company’s most recent announcement. “SuperCom continues to strengthen its position as a trusted partner for government agencies seeking effective, scalable solutions for public safety. With each new deployment, we help authorities enhance victim protection and offender compliance, driving real impact in communities.”

SuperCom uses both radio frequency (“RF”) and GPS, the dominant technologies in the EM market, to provide at-home and on-the-street supervision of offenders by the criminal justice system, which is suited to clients’ needs.

The company’s advanced PureTrack GPS platform includes branded technology elements such as the wearable bracelets PureOne (GPS) and the PureTag (RFID), the home base station PureCom, and the PureProtect mobile app.

SuperCom has a track record of more than 50 government clients served, monitoring more than 100,000 individuals.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

• SolarBank and Viridi are collaborating on a 3.06 MW solar and 1.2 MWh battery energy storage system in Buffalo, New York, repurposing a closed landfill, converting unused land into a source of clean energy.
• Pending approvals and financing, SolarBank is set to begin construction, while Viridi will provide the battery storage system.
• Viridi’s battery systems include integrated fire suppression and anti-propagation technology to enhance safety.
• Once operational, the project will function under a community solar model, where residents can subscribe to the project, earning credits on their electricity bills without installing personal solar panels.

Disseminated on behalf of SolarBank Corporation

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., has announced a partnership with Viridi, the industry leader in fail-safe battery energy storage systems (“BESS”), to develop a combined 3.06 megawatt (“MW”) direct current ground-mounted solar power project and a 1.2 megawatt-hour (“MWh”) BESS, in Buffalo, New York. This initiative aims to transform a closed landfill into a productive asset that generates clean energy for the local community (https://ibn.fm/XEmgk).

The selected site, located at 1037 South Park Ave. in South Buffalo, was previously a landfill. By repurposing this land, the project not only addresses environmental concerns but also contributes to the community by providing a sustainable energy source. This approach exemplifies innovative land use, turning otherwise unusable areas into hubs for renewable energy production.

Once operational, the project will function under a community solar model. This setup allows local residents, including renters and homeowners, to subscribe to the solar project. Subscribers receive credits on their electricity bills corresponding to their share of the generated solar energy, enabling them to benefit from renewable energy without the need to install personal solar panels. This model promotes inclusivity and broad participation in clean energy initiatives.

Viridi, known for its leadership in fail-safe battery energy storage systems, will supply the BESS for this project. Their innovative lithium-ion battery packs are equipped with integrated fire suppression and pioneering anti-propagation technology. Unlike traditional methods that modify battery cells, Viridi’s design isolates each cell to prevent thermal runaway, ensuring that a single cell failure does not escalate. This fail-safe approach enhances safety and reliability, making the energy storage solution adaptable for various settings.

SolarBank, subject to the receipt of financing, intends to be the owner of the project. The company has secured a lease for the project site and has applied for interconnection approval. Upon receiving the necessary permits and financing, the company plans to commence construction. The integration of the BESS with the solar installation will allow for the storage of generated energy, which can be dispatched during peak demand periods, thereby enhancing grid stability and optimizing energy use. This project aligns with New York State’s energy storage roadmap, which supports the development of such hybrid generation-storage projects.

SolarBank has already begun construction on another BESS project, representing the company’s first foray into this sector. The company has kicked off construction of project SFF-06, one out of two battery energy storage systems in Ontario, earlier in February 2025, through a $25.8 million CAD ($18.17 million USD) project finance facility from the Royal Bank of Canada. The initiatives come as battery storage demand surges, with the global market projected to reach $31.2 billion USD by 2029, growing at 16.3% annually (https://ibn.fm/G6g5b).

For more information, visit the company’s website at SolarBankCorp.com. This report contains forward looking information. Please refer to https://ibn.fm/G76GJ for additional details.

NOTE TO INVESTORS: The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

• Brera Holdings, an Ireland-based, international holding company with a global portfolio of men’s and women’s sports clubs, remains on track to acquire a 52% stake in Italian Serie B soccer club SS Juve Stabia
• Its investments are paying off, with Andrea Adorante, a star forward on the team, now having an estimated purchase value of close to €6-7 million, projected to climb to €8-10 million should he continue at his current goal-scoring pace
• Adorante has scored 12 goals with 2 assists so far in the current football season and could end up with 18 at that pace, winning fans and media, plus Player of the Week on the 26^th week of the season
• Adorante’s valuation could surpass Brera’s €7.5 million investment for its SS Juve Stabia acquisition, as well as the Nasdaq company’s current estimated overall valuation, all pointing to a massive overlooked opportunity for any investor

Brera Holdings (NASDAQ: BREA), an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership (“MCO”) approach, remains on track to acquire a 52% stake in Italian Serie B club, SS Juve Stabia “The Second Team of Naples.” Andrea Adorante, a star forward at the team, already has an estimated purchase value of between €6 to €7 million, projected to climb to €8-10 million should he continue at his current pace, according to Italian media reports. 

Brera Holdings, with a portfolio comprising six teams globally covering primarily both men’s and women’s football clubs, currently holds a 38.46% ownership equity in Juve Stabia, with the third and last of the multi-step acquisition set to close on March 31, 2025, making Brera the majority shareholder in the club (https://ibn.fm/XchS6).

Amazingly, this means that a single player for the Brera club Juve Stabia has an estimated asset sales value as high as that of the current full purchase price Brera is paying for its majority ownership of The Second Team of Naples, making it a significant overlooked opportunity for investors.

Earlier in February, it was estimated in an independent CFA research report that Juve Stabia’s 2025 revenue would increase by $5.15 million, with Brera’s overall revenue forecast estimated at between $6.3 million and $9.8 million. The projections have implied a market capitalization of $55.76 million by 2027, further projecting its MCO model’s viability (https://ibn.fm/W7S1D).

“Brera Holdings has made a strategic move with the Juve Stabia acquisition, and while challenges remain, the company is positioning itself for significant revenue growth,” noted Sascha P. Czerwenka, CFA, for 247MarketNews.com. “If operational improvements continue as expected, the stock could see a major re-rating, presenting a compelling opportunity for investors,” he added (https://ibn.fm/W7S1D).

So far in the current football season, Adorante has scored 12 goals and is projected to end up with 18 for the season. This impressive feat marks a striking year since he joined Juve Stabia on January 4, 2024. The 25-year-old Italian has made 25 match appearances for Juve Stabia, getting two assists in addition to his 12 goals (https://ibn.fm/OSsHd). He has also won accolades, including Player of the Week on the 26^th week of the current season, and has become a media and fan star. 

Having a single player with a higher estimated purchase value than that of the overall club, let alone the Nasdaq-listed company Brera that owns it, makes no sense, and should represent a hidden buying opportunity to any investor.

For company information, visit the company’s website at www.BreraHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA

• One of the most significant challenges facing biotechnology companies is securing adequate funding to sustain research and development efforts.
• Calidi’s improved financial footing reassures investors and allows the company to focus on achieving key milestones in its research pipeline.
• The company has been selected to present new data on its RTNova systemic virotherapy platform at the prestigious AACR annual meeting in April 2025.

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company, is making significant strides in the field of cancer immunotherapy. Known for its innovative approach to antitumor virotherapies, Calidi is focused on harnessing the power of its patented technology that protects and potentiates the virotherapy during administration (extracellular enveloped viruses in its systemic platform and stem cells in its intratumoral platforms) to target and destroy cancer cells while simultaneously stimulating the immune system. The company’s groundbreaking work has positioned it as a leader in the development of next-generation cancer treatments.

In recent news, Calidi has made two major announcements that underscore its progress, one related to its strengthened financial position and another highlighting its acceptance into a prestigious scientific seminar to present new research. These developments signal the company’s growth and its continued advancement toward commercializing its therapies.

One of the most significant challenges facing biotechnology companies is securing adequate funding to sustain research and development efforts. Calidi Biotherapeutics recently announced that it has strengthened its financial position, ensuring continued progress in its clinical and preclinical programs (https://ibn.fm/9JicX). As of Dec. 31, 2024, Calidi reported a cash balance of approximately $9.6 million. This increase is largely due to successful fundraising efforts, including proceeds from the company’s At-the-Market Offering Agreement (“ATM”).

As a result of these efforts, Calidi was able to terminate its Standby Equity Purchase Agreement (“SEPA”) with YA II PN Ltd., an affiliate of Yorkville Advisors, effective Jan. 23, 2025. The infusion of capital will allow the company to further refine its oncolytic virotherapy platforms, expand its clinical trials, and enhance its overall operational stability.

Additionally, Calidi announced the successful closing of a public offering on Jan. 10, 2025, which raised an additional $4.25 million in gross proceeds. This contributes to the ongoing development of Calidi’s proprietary technologies and supports the company’s mission to bring effective cancer therapies to market. This improved financial footing not only reassures investors but also allows Calidi to focus on achieving key milestones in its research pipeline. With adequate funding in place, the company is well-positioned to continue its groundbreaking work in cancer immunotherapy.

Beyond its financial achievements, Calidi Biotherapeutics has also made headlines for its acceptance into a major scientific conference where it will present its latest research findings (https://ibn.fm/WZ1RO). The company announced that it has been selected to present new data on its RTNova systemic virotherapy platform at the prestigious American Association for Cancer Research (“AACR”) annual meeting in April 2025.

This recognition marks an important milestone for Calidi, as the AACR annual meeting is one of the most influential conferences in the field of cancer research. Being accepted to present at this event underscores the significance of Calidi’s work and its potential to revolutionize cancer treatment.

Calidi’s RTNova platform is designed to overcome the limitations of traditional virotherapy by enabling systemic delivery and enhancing the targeting of metastatic tumors. Antitumor virotherapies have long been recognized for their ability to selectively infect and kill cancer cells, but challenges such as immune system clearance and limited distribution have hindered their full potential. The RTNova platform addresses these challenges by utilizing an extracellular enveloped virus (“EEV”) as a delivery mechanism, allowing the therapeutic viruses to reach tumors more effectively while evading premature destruction by the immune system. These preclinical findings highlight the RTNova platform’s ability to effectively target and treat metastatic cancer cells and represent a significant advancement in the field of cancer virotherapy.

In addition to the RTNova platform, Calidi is actively developing other innovative therapies aimed at harnessing the immune system to combat cancer. The company’s approach to immunotherapy focuses on protecting the viral payload to enhance the efficacy of antitumor viruses, potentially improving outcomes for patients with hard-to-treat cancers.

With a strengthened financial position and the recognition of its research by a leading scientific organization, Calidi Biotherapeutics is poised for continued growth. The company’s ability to secure funding ensures that it can maintain momentum in its clinical and preclinical programs, while its acceptance into a high-profile scientific seminar validates the importance of its work. As Calidi moves forward, it is well-positioned to make a lasting impact in the biotechnology industry. With continued innovation and a strong financial foundation, the company is set to play a crucial role in the future of cancer immunotherapy.

For more information, visit www.CalidiBio.com.

NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI

• Adageis streamlines complex insurance contracts, helping providers maximize reimbursements.
• The company’s AI-driven solutions reduce administrative burden, freeing up time for patient care.
• Seamless integration with nearly 100 EHR systems ensures a smooth transition to value-based care models.
• The company’s fintech approach enhances financial performance, with providers seeing up to $75,000 in additional revenue.
• Adageis projects significant growth, expecting to cover 580,000 patient lives by mid-2025.

Healthcare is shifting toward value-based care, where providers are reimbursed for patient outcomes rather than the number of procedures performed. While the model promises higher-quality care at lower costs, it also introduces complex reimbursement structures that can be difficult to navigate.

Adageis, a healthcare technology company providing smart AI-centric software solutions for healthcare organizations, is helping providers optimize care delivery while maximizing revenue. The company’s AI-driven platform integrates with nearly 100 electronic health record (“EHR”) systems, making it easy for medical practices to track performance metrics and meet insurers’ evolving documentation requirements.

“One of the major challenges in the marketplace is the sheer complexity — there are over 100 insurance companies with more than 1,000 plans in the Phoenix area alone. Each has different measures and unique documentation requirements… Adageis has a solution that integrates with nearly 100 electronic health record systems, overlaying existing platforms to provide easy-to-read measures tailored to each patient’s insurance,” Adageis CEO Shane Speirs said during a recent podcast (https://ibn.fm/7yFnW).

According to Speirs, what Adageis focuses on is to provide a simple solution to healthcare organizations — ranging from large, multi-state, multi-specialty healthcare groups to independent practices across the country. “We offer a solution that meets everyone’s needs, helping providers and organizations drive revenue by delivering high-quality care, which everyone can align with,” the Adageis CEO said. “Much of the value in value-based care comes from providing proper documentation to patients and being proactive with screenings. We provide an easy solution for practices to indicate the metrics needed for patients, to provide high-quality care while maximizing incentive dollars.”

Another issue the healthcare system is facing is the fact that administrative tasks, such as clinical documentation and coding, consume valuable time that could be spent on patient care. Adageis addresses this issue with its AI Scribe technology, which uses ambient listening to automate documentation and coding. By leveraging AI, the platform:

• Reduces administrative workload, allowing providers to focus on patient care.
• Generates high-quality coding, ensuring maximum reimbursement.
• Minimizes errors in documentation, lowering the risk of rejected claims.

This approach enhances financial performance, with some providers seeing up to $75,000 in additional annual revenue from value-based care incentives, according to figures listed in the company’s investor deck.

Adageis is positioning itself as a leader in healthcare fintech, as the only healthcare fintech company in the marketplace, bridging the gap between financial optimization and improved patient care. The company’s growth projections underscore its increasing market presence:

• Currently covering 150,000 patient lives, with plans to reach 580,000 by mid-2025.
• $100,000 in monthly recurring revenue expected by Q2 2025.
• Expanding provider base, onboarding 2-3 new clients per month.

By integrating financial technology with AI-driven healthcare solutions, Adageis is reshaping how providers approach value-based care, ensuring better patient outcomes while driving revenue growth. Allowing providers to simplify complex financial structures while maintaining quality care, Adageis offers a scalable, easy-to-implement platform, reducing inefficiencies and ensuring forward-thinking providers thrive in a rapidly evolving landscape.

For more information, visit the company’s website at www.Adageis.com.

NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis

Traders, dealers, businesses, and enthusiasts of the cannabis industry are invited to attend the New England Cannabis Convention in Boston from March 21 to March 22, 2025. Operating since 2015, NECANN events are referred to as “MJBizCon East.” The second largest B2B event in the U.S., NECANN witnesses thousands of attendees, with the largest gathering of licensed operators, exhibitors, buyers, and leaders, for the East Coast cannabis market. These events are considered the home base for the Northeast cannabis industry.

The Boston NECANN Convention 2025 will also host the prize-giving ceremony for the Boston NECANN Cup winners on March 22, 2025. Registrations for this close on February 23, 2025. Applications are also invited to judge the NECANN Boston Cup. The NECANN Cup is New England’s only multi-state cannabis competition, a third-party blind evaluation of cannabis and cannabis products (https://ibn.fm/duCNZ).

NECANN events are considered a major benefit to the Northeast cannabis industry, offering a phenomenal platform for networking and business to the local cultivators, traders, pharmacies, and more. Each year, the event witnesses 9,000+ attendees, interacting, networking, and attending the 60+ programming sessions. Over 300+ exhibitors, with 100+ licensed cultivators, retailers, and brands, exhibit their latest products and technologies on the exhibition floor.

Investors can discover new avenues of investment while entrepreneurs can gain visibility among the leading businesses and experts in the cannabis industry. Cannabis industry stalwarts will conduct the different programming sessions at NECANN Boston. They will address the most compelling cannabis industry topics faced by operators in Massachusetts. Some important topics that will be covered include regulatory compliance services, consumer market study, and advocacy of psychedelic-assisted therapies in conservative states, to name a few.

To learn more, please visit https://ibn.fm/KSQ7t.